pamidronate has been researched along with Carcinoma, Renal Cell in 6 studies
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
Excerpt | Relevance | Reference |
---|---|---|
"Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 7.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
"Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 3.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
"We report a renal cell carcinoma case in which multiple lung and bone metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 mg zoledronate once, and weekly 10 mg incadronate 10 times for 3 months." | 1.35 | Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. ( Fujii, Y; Fukui, I; Kijima, T; Okubo, Y; Suyama, T; Yonese, J, 2008) |
"Zoledronic acid was consistently more potent than pamidronate for inducing apoptotic cell death." | 1.33 | Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. ( Anderson, C; Birchall, L; Harrington, K; Meyer, B; Pandha, H; Relph, K; Wilson, N, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (33.33) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
McKay, RR | 1 |
Lin, X | 1 |
Perkins, JJ | 1 |
Heng, DY | 1 |
Simantov, R | 1 |
Choueiri, TK | 1 |
Pandha, H | 1 |
Birchall, L | 1 |
Meyer, B | 1 |
Wilson, N | 1 |
Relph, K | 1 |
Anderson, C | 1 |
Harrington, K | 1 |
Kijima, T | 1 |
Fujii, Y | 1 |
Suyama, T | 1 |
Okubo, Y | 1 |
Yonese, J | 1 |
Fukui, I | 1 |
Kise, H | 1 |
Kobayashi, K | 1 |
Arima, K | 1 |
Yanagawa, M | 1 |
Tochigi, H | 1 |
Kawamura, J | 1 |
Hioki, T | 1 |
Sugiura, Y | 1 |
Akbulut, H | 1 |
Icli, F | 1 |
Morton, AR | 1 |
Friefeld, J | 1 |
Halperin, F | 1 |
6 other studies available for pamidronate and Carcinoma, Renal Cell
Article | Year |
---|---|
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Dens | 2014 |
Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Death; Cell Line, Tumor; Cell Prolifer | 2006 |
Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imi | 2008 |
[Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Hypercalcemia; | 1996 |
Overdosage of pamidronate in a patient with renal cell carcinoma.
Topics: Aged; Anti-Inflammatory Agents; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Hypercalcemia | 2000 |
Dose of bisphosphonate for hypercalcaemia of malignancy.
Topics: Aged; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Intravenous; | 1990 |